Lakefront Biotherapeutics | GLPG - Current Liabilities


Lakefront Biotherapeutics reported EUR70.32M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
GRIFOLS EUR 2.3B 59M Sep/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Incyte USD 1.44B 125.72M Sep/2026
Merck EUR 8.96B 833M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
UCB EUR 4.4B 470M Dec/2025
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026